دورية أكاديمية

The clinical efficacy of azathioprine as maintenance treatment for autoimmune pancreatitis: a systematic review and meta-analysis

التفاصيل البيبلوغرافية
العنوان: The clinical efficacy of azathioprine as maintenance treatment for autoimmune pancreatitis: a systematic review and meta-analysis
المؤلفون: Masaki, Yoshiharu, Nakase, Hiroshi, Tsuji, Yoshihisa, Nojima, Masanori, Shimizu, Kyoko, Mizuno, Nobumasa, Ikeura, Tsukasa, Uchida, Kazushige, Ido, Akio, Kodama, Yuzo, Seno, Hiroshi, Okazaki, Kazuichi, Nakamura, Seiji, Masamune, Atsushi
المصدر: Journal of Gastroenterology ; volume 56, issue 10, page 869-880 ; ISSN 0944-1174 1435-5922
بيانات النشر: Springer Science and Business Media LLC
سنة النشر: 2021
مصطلحات موضوعية: Gastroenterology
الوصف: The effectiveness of azathioprine (AZA) in preventing relapse and maintaining autoimmune pancreatitis (AIP) remission has been reported; however, most of these studies are case series with no randomized control trials available in the literature. Therefore, this study performed a systematic review and meta-analysis of the existing literature on this subject to determine the clinical efficacy of AZA as maintenance therapy for AIP patients. A systematic search was performed to identify studies on the clinical efficacy of AZA as maintenance therapy in AIP patients. The crude multiple relapse rate was estimated to assess the ability of AZA to control relapses in AIP. Pooled estimates were obtained using a random-effects model with the DerSimonian-Laird method. We identified AIP patients who did not respond to initial steroid treatment, experienced steroid weaning failure, or those who relapsed during remission as refractory cases. After reviewing the studies, ten articles fulfilled the inclusion criteria and were selected for meta-analysis. Of all 4504 patients, 3534 patients were treated with steroids, and 346 patients were treated with AZA for relapsed AIP. In this meta-analysis, 14/73 (19.2%) patients receiving AZA for refractory AIP relapsed. Meanwhile, 14/47 (29.8%) patients without AZA experienced relapse. The integrated odds ratio for relapse risk in patients receiving AZA was estimated to be 0.52 ( p = 0.15). This systematic review and meta-analysis demonstrated the efficacy of AZA in preventing relapse of AIP, which supports the use of AZA as a maintenance treatment in patients with AIP who relapse upon withdrawal of steroid therapy.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1007/s00535-021-01817-9
DOI: 10.1007/s00535-021-01817-9.pdf
DOI: 10.1007/s00535-021-01817-9/fulltext.html
الإتاحة: https://doi.org/10.1007/s00535-021-01817-9Test
حقوق: https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test
رقم الانضمام: edsbas.189C5F25
قاعدة البيانات: BASE